Impact of Febuxostat on Renal Function in Gout Patients With Moderate‐to‐Severe Renal Impairment

Abstract

Febuxostat proved to be efficacious in serum UA reduction and was well tolerated in gout patients with moderate-to-severe renal impairment. Patients randomly assigned to receive febuxostat demonstrated significantly lower serum UA levels and no significant deterioration in renal function.